Company news

Cynata Therapeutics Limited news in 2024

Cynata Therapeutics Limited's news releases, calls and decks from 2024, newest first.

View company

First Kidney Transplant Trial Patient Treated

December 11, 2024

Cynata secures commitments for $8.1m institutional placement

December 5, 2024

Demonstrated Safety & Efficacy in DFU Clinical Trial

December 5, 2024

Trading Halt

December 3, 2024

Cynata Receives $1.88m R&D Tax Incentive Refund

November 26, 2024

Study of Cymerus MSCs in Pulmonary Fibrosis Published

August 8, 2024

Cynata to Acquire IP from Tekcyte

July 1, 2024

Further GvHD Clinical Data Published in Nature Medicine

May 22, 2024

DFU Clinical Trial Enrolment Complete

April 7, 2024

EU Approval for Phase 2 CYP-001 Trial in GvHD

March 19, 2024

First Patient Treated in Phase 2 GvHD Trial

March 4, 2024

Encouraging Initial Data from CYP-006TK DFU Trial

February 25, 2024

Decks in 2024